Skip directly to content

Lower Risk of Breast Cancer Recurrence

 

Inspired to Be Informed

 

Lower Risk of Breast Cancer Recurrence

The risk of breast cancer recurrence was lower for women who switched to AROMASIN®
(exemestane tablets) after 2 to 3 years of treatment with tamoxifen than for women who stayed on tamoxifen for 5 years.

Women who experienced breast cancer recurrence (local or metastatic recurrence, contralateral breast cancer or death) after almost 3 years (34.5 months) in the study
AROMASIN
Patients
(n=2,352)
213
Tamoxifen
Patients
(n=2,372)
306

Absolute risk reduction

Fewer (4% less) women experienced breast cancer recurrence in the AROMASIN group than in the tamoxifen group

Relative risk reduction

31% lower risk of
breast cancer recurrence

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.

Almost 5 years in the study, results continued

Women who experienced breast cancer recurrence (local or metastatic recurrence, contralateral breast cancer or death) after almost 5 years (52.4 months) in the study
AROMASIN
Patients
(n=2,352)
354
Tamoxifen
Patients
(n=2,372)
453

Absolute risk reduction

Fewer (4% less) women experienced breast cancer recurrence in the AROMASIN group than in the tamoxifen group

Relative risk reduction

24% lower risk of
breast cancer recurrence

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.